XenoTech Plans Expansion to New Global Headquarters
News Apr 22, 2015
Contract Research Organization XenoTech, LLC, a division of Sekisui, has announced plans to relocate into a new 41,500 ft2 facility. The planned move will double the size of XenoTech’s global headquarters, currently located at 16825 W. 116th St. in Lenexa, KS. The new facility, boasting nearly two and a half times the customized laboratory space, will remain in the Kansas City metro area, just blocks away from where the company was founded more than twenty years ago. Remaining in the Kansas City area maintains the company’s central location, ideal for quick access to both the East and West coasts of the United States. XenoTech is expected to complete the move into the new global headquarters in late fall, 2015.
XenoTech’s new location will serve as the global headquarters for their contract research business, providing the space necessary for an expanding range of services covering discovery through clinical support. XenoTech’s world-renowned in vitro products will continue to be produced within the new headquarters and will be used to support the contract research business conducted on-site. “XenoTech provides a variety of in vitro products and reagents to companies worldwide. We are known for our world-class services, but our in-house manufacturing of products not only helps to facilitate our global customers’ internal research efforts, but also provides the solid foundation behind our in vitro ADME / DDI service expertise. Our products are distributed in over 25 countries worldwide and we have a product catalog more than 90 pages long,” said Christian Darabant, VP of Commercial Operations.
XenoTech experienced impressive growth during fiscal year 2014, seeing record bookings and a greater than 15% increase in revenue over 2013. This growth was not only fuelled by an increasing demand for the company’s core ADME / DMPK / DDI expertise but also an ongoing expansion of related products and services designed to maximize convenience, study consistency and efficiency for XenoTech’s customers. This has resulted in an increase in the company’s client base and demand for the company’s products and services, requiring additional employees and an expanded facility.
XenoTech COO, Jason Neat, explained, “Relocating our headquarters both facilitates and compliments XenoTech’s dedication to expanding into natural extensions of our core ADME business. We take our reputation within the in vitro ADME-DMPK market very seriously, and we will not lose sight of our core expertise. Instead, this move allows us to grow naturally into complementing areas around our DMPK expertise, expanding our offerings to match the needs of our customers to reduce the time, expense and headache involved in bringing a drug to market.”
“XenoTech’s vision is to be the world’s foremost facilitator in the pursuit of life-enhancing therapies, and we are one step closer to that goal with the expansion into our new building. We will use the new space to drive scientific innovation and expand our offerings to ensure clients the quality they have come to expect from XenoTech, in a wider array of services, at even more attractive timelines,” added Neat.
The relocation also provides benefits to the Kansas City, KS community. XenoTech hired 11 full-time staff members over the course of 2014 and is planning continued expansion of its workforce throughout the next few years. XenoTech employees bring a community-focused outlook to the region and have raised nearly $250,000 in charitable donations and given countless hours of personal time towards community outreach and philanthropic events.
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
Agilent Expands Cell Analysis Portfolio with Acquisition of Luxcel BiosciencesNews
Focused R&D expansion providing core competencies in biosensor chemistries and bioassay solutions targeting pharma/biopharma applications for near and long-term portfolio expansion.READ MORE